Metraipolis › archive › dc_edae97ef914d

Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab — Europe PMC PMID:41532856

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41532856
DOI
10.1158/2159-8290.cd-25-1483
License (as archived)
solo-consultazione
Archived
2026-11-02T21:42:27.321Z
SHA-256 of the archived text
0af98a4253af778aa31dabb58f3bdb5d06555aa7aaf156cb5f6be1b7d964ebee
Stable URL of this page
https://metraipolis.com/documento/dc_edae97ef914d

How to cite

Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab — Europe PMC PMID:41532856 — Europe PMC (en), https://europepmc.org/article/MED/41532856 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_edae97ef914d (Metraipolis archive dc_edae97ef914d, sha256 0af98a4253af778aa31dabb58f3bdb5d06555aa7aaf156cb5f6be1b7d964ebee)
BibTeX
@misc{dcedae97ef914d,
  title = {Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab — Europe PMC PMID:41532856},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41532856},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_edae97ef914d; sha256 0af98a4253af778aa31dabb58f3bdb5d06555aa7aaf156cb5f6be1b7d964ebee},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41532856. Agents can read the archived copy with the MCP tool read_document.